Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
The Motley Fool February 10, 2009 Brian Orelli	Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool February 29, 2008 Brian Lawler	FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.
The Motley Fool December 14, 2009 Brian Orelli	Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa.
The Motley Fool August 14, 2009 Brian Orelli	The Schizophrenic Drug Approval Schering's drug gets a thumbs-up.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
BusinessWeek March 11, 2010 Margaret Cronin Fisk et al.	Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.
The Motley Fool August 27, 2009 Brian Orelli	Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan
The Motley Fool January 8, 2009 Brian Orelli	FDA Toys With Lilly, and Investors, Again Eli Lilly will have to wait a little longer.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool July 5, 2011 Brian Orelli	Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important.
The Motley Fool April 21, 2010 Brian Orelli	Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant.
The Motley Fool January 5, 2010 Brian Orelli	Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool January 31, 2008 Brian Lawler	A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool December 29, 2003 Alyce Lomax	Lilly's Symbyax Gets Green Light Prozac has a new lease on life. The Food and Drug Administration recently approved Eli Lilly's well-known antidepressant in combination with Zyprexa for the treatment of bipolar depression.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool January 14, 2009 Brian Orelli	FDA's Bipolar Decision on Schering's Drug Signs point to an approval for Schering-Plough's schizophrenia and bipolar drug Saphris, but there isn't one yet.
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool October 13, 2010 Brian Orelli	Don't Get Addicted to Alkermes' Low Revenue Vivitrol's launch and the approval of Bydureon will drive revenue -- and Alkmeres' stock price -- in the future.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 13, 2009 Brian Orelli	J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
Wired September 25, 2007 Patrick Di Justo	From Benzedrine to Abilify, Chronicling America's Love of Psychiatric Drugs A history of what Americans have used to battle depression.
Chemistry World March 26, 2014 Phillip Broadwith	$1.2bn J&J deceptive marketing fine overturned The Arkansas Supreme Court has overturned a lower court's fine of $1.2 billion, imposed on Johnson & Johnson's subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone).
The Motley Fool October 7, 2010 Anders Bylund	Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson.
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool May 29, 2009 Brian Orelli	Delayed, Reason Unknown As long as Bayer and Johnson & Johnson can answer the FDA's questions relatively quickly, it shouldn't affect the companies too much.
The Motley Fool October 30, 2007 Brian Lawler	Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool April 7, 2011 Brian Orelli	Restless No Longer XenoPort and Glaxo get a delayed FDA approval.
The Motley Fool December 27, 2006 Brian Lawler	Alkermes' Japanese Opportunity With Japan commanding over 10% of global pharmaceutical sales and Risperdal sales gaining ground, there will be big bucks for Alkermes if Risperdal can gain marketing approval over there.
Chemistry World September 11, 2013 Phillip Broadwith	First biosimilar antibody drugs approved in Europe The European commission has given final marketing approval to the first generic versions of monoclonal antibody drug infliximab (Johnson & Johnson's Remicade).
The Motley Fool February 20, 2004 Alyce Lomax	A Downer for Lilly? The pharmaceutical giant confirms warnings on Zyprexa and the elderly. That warning had to do with a higher incidence of stroke in elderly users suffering from dementia.